Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

BACKGROUND: Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Pol, Tymon, Held, Claes, Westerbergh, Johan, Lindbäck, Johan, Alexander, John H., Alings, Marco, Erol, Cetin, Goto, Shinya, Halvorsen, Sigrun, Huber, Kurt, Hanna, Michael, Lopes, Renato D., Ruzyllo, Witold, Granger, Christopher B., Hijazi, Ziad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850246/
https://www.ncbi.nlm.nih.gov/pubmed/29419390
http://dx.doi.org/10.1161/JAHA.117.007444

Ejemplares similares

Ejemplares similares